Clinical trials: Myasthenia Gravis, Generalized
Myasthenia Gravis, Generalized
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
The purpose of the HARMONY 360 investigation is to explore the feasibility of using MyoSense 360 digital measures to develop models capable of detecting clinically meaningful changes in generalized Myasthenia Gravis (gMG)…
- Trial name
- HARMONY 360 (NCT07323316)
- Testing
- MyoSense 360
- Volunteers
- 100 people
- Sponsor
- Ad scientiam
Generalized Myasthenia Gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NIMBLE (NCT05070858)
- Testing
- Pozelimab + Cemdisiran, Cemdisiran, Pozelimab
- Where
- 116 sites in United States, Belgium and 17 more
- Volunteers
- 288 people
- Sponsor
- Regeneron Pharmaceuticals
Generalized Myasthenia Gravis (gMG)
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
This is a Phase Ib, open-label, dose-escalation, single-center/multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of multiple doses of EA5 (a humanized…
- Trial name
- NCT07818291
- Testing
- EA5
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Shanghai Lanyi Therapeutics Co., Ltd.
Myasthenia Gravis, Generalized
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT07647510
- Testing
- Claseprubart
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- Dianthus Therapeutics
Myasthenia Gravis
Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital - "My" Asthenia
After identifying myasthenic patients meeting the inclusion criteria, telephone contact with patients to suggest that they participate in the study by responding to various questionnaires composed of validated scales used in…
- Trial name
- NCT06877403
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Myasthenia Gravis, Generalized Myasthenia
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
- Conditions
- Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
- Trial name
- NCT06106672
- Testing
- CNP-106
- Where
- 17 sites in United States
- Volunteers
- 54 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Myasthenia Gravis, Generalized
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
- Trial name
- NCT03304054
- Testing
- Amifampridine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Myasthenia Gravis
A Study in Patients With Myasthenia Gravis in China
This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization…
- Trial name
- MG Cohort (NCT06700616)
- Where
- 20 sites in China
- Volunteers
- 1,199 people
- Sponsor
- AstraZeneca
Generalized Myasthenia Gravis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of…
- Trial name
- THYME (NCT06987539)
- Testing
- Inebilizumab
- Where
- 14 sites in United States, Argentina and 6 more
- Volunteers
- 15 people
- Sponsor
- Amgen
Generalized Myasthenia Gravis, gMG
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
- Trial name
- NCT05644561
- Testing
- Ravulizumab
- Where
- 11 sites in United States, Italy and 3 more
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Generalized Myasthenia Gravis
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab…
- Trial name
- NCT04202341
- Where
- 51 sites in United States, Austria and 5 more
- Volunteers
- 500 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myasthenia Gravis, Generalized
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.
- Trial name
- NCT02473952
- Testing
- IGIV-C
- Where
- 40 sites in United States, Belgium and 8 more
- Volunteers
- 62 people
- Sponsor
- Grifols Therapeutics LLC
Myasthenia Gravis, Myasthenia Gravis, Generalized
Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
Evaluate the feasibility of using digital health technologies to monitor symptoms in myasthenia gravis (MG). Study subjects will be screened and enrolled at Massachusetts General Brigham Hospital to participate in this 12 month…
- Trial name
- BioDigit MG-02 (NCT07224386)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- BioSensics
Generalized Myasthenia Gravis (gMG)
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the…
- Trial name
- NCT07058298
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Daishi Tian
Myasthenia Gravis, Myasthenia Gravis, Generalized
A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Trial name
- NCT04224506
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Generalized Myasthenia Gravis
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
- Trial name
- NCT04124965
- Testing
- Rozanolixizumab
- Where
- 43 sites in United States, Canada and 10 more
- Volunteers
- 71 people
- Sponsor
- UCB Biopharma SRL
Myasthenia Gravis Generalized
Markers of Favorable Response to FcRn Inhibitors(INFORM)
Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction.
- Trial name
- INFORM (NCT06685055)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Myasthenia Gravis
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study…
- Trial name
- NCT05332210
- Testing
- HBM9161 Injection (680mg)
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.